Table 4 The association of clinicopathological parameters with overall, cancer-specific and disease-free survival in patients
Characteristics | Total | Overall survival | P* | Cancer-specific survival | P* | Disease-free survival | P* | |
|---|---|---|---|---|---|---|---|---|
n(%) 389 | n(%) of patients with death (n = 270) | n(%) of patients with death (n = 235) | n(%) of patients with recurrence (n = 302) | |||||
Sex | Female | 107 (27.5%) | 72 (26.7%) | 0.518 | 66 (28.1%) | 0.629 | 80 (26.5%) | 0.279 |
Male | 282 (72.5%) | 198 (73.3%) | 169 (71.9%) | 222 (73.5%) | ||||
Age (years) | <65 | 185 (47.6%) | 111 (41.1%) | 0.000 | 98 (41.7%) | 0.000 | 132 (43.7%) | 0.001 |
≥65 | 204 (52.4%) | 159 (58.9%) | 137 (58.3%) | 170 (56.3%) | ||||
Alcohol | Yes | 73 (18.8%) | 48 (17.8%) | 0.437 | 43 (18.3%) | 0.439 | 55 (18.2%) | 0.601 |
No | 316 (81.2%) | 222 (82.2%) | 192 (81.7%) | 247 (81.8%) | ||||
Tobacco | Yes | 72 (18.5%) | 56 (20.7%) | 0.152 | 49 (20.9%) | 0.125 | 61 (20.2%) | 0.326 |
No | 317 (81.5%) | 214 (79.3%) | 186 (79.1%) | 241 (79.8%) | ||||
Family history | Yes | 15 (3.9%) | 9 (3.3%) | 0.557 | 8 (3.4%) | 0.554 | 14 (4.6%) | 0.005 |
No | 374 (96.1%) | 261 (96.7%) | 227 (96.6%) | 288 (95.4%) | ||||
Histological type | papillary | 19 (4.9%) | 10 (3.7%) | 0.163 | 9 (3.8%) | 0.249 | 11 (3.6%) | 0.041 |
tubular | 81 (20.8%) | 53 (19.6%) | 45 (19.1%) | 59 (19.5%) | ||||
   poorly differentiated | 203 (52.2%) | 148 (54.8%) | 126 (53.6%) | 165 (54.6%) | ||||
| Â | mucinous | 57 (14.7%) | 37 (13.7%) | 35 (14.9%) | 43 (14.2%) | |||
   signetring cell | 29 (7.4%) | 22 (8.1%) | 20 (8.5%) | 24 (7.9%) | ||||
Tumor grade | G1-G2 | 214 (55.0%) | 139 (51.5%) | 0.061 | 127 (54.0%) | 0.168 | 159 (52.6%) | 0.044 |
G3-G4 | 175 (45.0%) | 131 (48.5%) | 108 (46.0%) | 143 (47.4%) | ||||
Tumor stage | I-II | 159 (40.9%) | 60 (22.2%) | 0.000 | 52 (22.1%) | 0.000 | 85 (28.1%) | 0.000 |
III-IV | 230 (59.1%) | 210 (77.8%) | 183 (77.9%) | 217 (71.9%) | ||||
Depth of invasion | T1-T2 | 66 (17.0%) | 18 (6.7%) | 0.000 | 16 (6.8%) | 0.000 | 35 (11.6%) | 0.000 |
T3-T4 | 323 (83%) | 252 (93.3%) | 219 (93.2%) | 267 (88.4%) | ||||
Lymph node | N0 | 72 (18.5%) | 17 (6.3%) | 0.000 | 15 (6.4%) | 0.000 | 34 (11.3%) | 0.000 |
N1-N3 | 317 (81.5%) | 253 (93.7%) | 220 (93.6%) | 268 (88.7%) | ||||
Distance metastasis | M0 | 235 (60.4%) | 121 (44.8%) | 0.000 | 106 (45.1%) | 0.000 | 150 (49.7%) | 0.000 |
M1 | 154 (39.6%) | 149 (55.2%) | 129 (54.9%) | 152 (50.3%) | ||||
CEA (ng/ml) | ≤5 | 243 (62.5%) | 149 (55.2%) | 0.000 | 131 (55.7%) | 0.000 | 176 (58.3%) | 0.000 |
>5 | 146 (37.5%) | 121 (44.8%) | 104 (44.3%) | 126 (41.7%) | ||||
CA199 (U/ml) | ≤37 | 278 (71.5%) | 175 (64.8%) | 0.000 | 151 (64.3%) | 0.000 | 203 (67.2%) | 0.000 |
>37 | 111 (28.5%) | 95 (35.2%) | 84 (35.7%) | 99 (32.8%) | ||||
NLR | <2.36 | 132 (33.9%) | 64 (23.7%) | 0.000 | 54 (23.0%) | 0.000 | 81 (26.8%) | 0.000 |
≥2.36 | 257 (66.1%) | 206 (76.3%) | 181 (77.0%) | 221 (73.2%) | ||||
dNLR | <1.85 | 151 (38.8%) | 79 (29.3%) | 0.000 | 68 (28.9%) | 0.000 | 98 (32.5%) | 0.000 |
≥1.85 | 238 (61.2%) | 191 (70.7%) | 167 (71.1%) | 204 (67.5%) | ||||
PLR | <132 | 165 (42.4%) | 100 (37.0%) | 0.001 | 83 (35.3%) | 0.001 | 117 (38.7%) | 0.002 |
≥132 | 224 (57.6%) | 170 (63.0%) | 152 (64.7%) | 185 (61.3%) | ||||
LMR | <4.95 | 241 (71.0%) | 192 (71.1%) | 0.000 | 173 (73.6%) | 0.000 | 205 (67.9%) | 0.000 |
≥4.95 | 148 (29.0%) | 78 (29.9%) | 62 (26.4%) | 97 (32.1%) | ||||